Johnson & Johnson expects lucrative return on drug pipeline
NEW BRUNSWICK, N.J. (AP) — Johnson & Johnson says its pharmaceutical business expects to seek regulatory approval by 2019 for more than 10 new products, each with the potential to top $1 billion in annual sales.
The health care products maker says its Janssen Pharmaceutical Companies business also will pursue approvals of more than 40 additional uses for existing or new products.
New Brunswick, New Jersey-based Johnson & Johnson is hosting a review of its pharmaceutical business with analysts. The company's drug portfolio focuses on five areas: immunology, infectious diseases and vaccines, neuroscience, cardiovascular and metabolism, and oncology.
Janssen also announced Tuesday that it is partnering with Achillion Pharmaceuticals Inc. to develop and sell hepatitis C treatments, a potential lucrative field for drugmakers.
Johnson & Johnson shares are climbing in early morning trading.